BGI and Maxwell Plus have executed a collaborative research project “A model to predict risk of developing advanced or metastatic prostate cancer using genetic makeup and family history of cancers”. The objective is to understand the genetic makeup of prostate cancer patients and understand how significant the association is between prevalence of prostate, breast, ovarian and colorectal cancers in patients' families. Keep reading
BGI signs a Memorandum of Understanding (MoU) with the bio-nanotechnology innovator Xing Technologies, a UQ spin-off enterprise specialising in world-leading disease diagnosis and monitoring technologies, including cancer. The partnership will focus on collaborative research and product innovation in DNB technology, Circulating Tumour/Stem Cells technology, and point-of-care product. Keep reading
Dr Andrew Carroll from DNAnexus conducted an independent side-by-side assessment of data comparison of BGISEQ 500 to Illumina NovaSeq on 2 Jul. 2018 and published the findings. The analysis is based on the three WGS data sets of NA12878/HG001 recently released, and demonstrates significant improvements relative to prior data. Keep reading
BGI signed a Memorandum of Understanding with the University of Queensland to strengthen the extensive collaboration to establish Australia's very own gene bank. “This is an important initiative that will help protect the world’s biodiversity, and lead to other innovations in food security and human health.” said Professor Robert Henry, Director of the Queensland Alliance for Agriculture and Food Innovation. Keep reading
On the latest Nature Index 2017 recently published, BGI ranks No.1 on the Top 50 Corporate Institutions by Number of Academic Collaborations with 642 bilateral collaborations worldwide from 2012 to 2016. Other major multinational corporations are also named on the index e.g. Illumina, Inc. ranks the 6th with 412 collaborations; Thermo Fisher the 13th with 333 collaborations. Keep reading
Professor George Church accepted the appointment as the Chief Scientist of the George Church Institute of Regenesis located in China National GeneBank, Shenzhen, China. BGI has made a strong commitment to support research directed by Prof. Church both in China and in the United States. The new collaboration of applied synthetic biology will initially focus on the development of enabling technologies in high-density DNA storage, biomanufacture of natural products, and genome editing for medicine and new therapy. Keep reading
Life Science research to benefit as global genomics specialist formalises ties with the University of Queensland Centre of Advanced Imaging (CAI) to develop early diagnostic tools for epilepsy. “It will combine anatomical imaging data from Australia’s first ultra-high field 7T MRI with whole genome sequencing data from participants who have intractable focal epilepsy,” the Director of UQ CAI Professor David Reutens said "the research collaboration with BGI was unique and was set to boost the centre’s research, development and commercialisation." Keep reading
BGI Australia and the University of Melbourne have signed a MOU to engage in scientific collaborations in the area of One Health using -omic and informatic technologies with the aim to build a comprehensive, world-class program and joint-centre in infectious diseases. The University’s Faculty of Veterinary and Agricultural Sciences and BGI will undertake an international-collaborative research program in areas such as genomics, transcriptomics, proteomics, bioinformatics and data mining. Keep reading
Since the announcement of call for proposals in August 2017 BGI Australia has received 21 Expression of Interest(EOI)’s and 3 full proposals. We are sincerely appreciative of the extensive interest received from our passionate fellow Australian researchers and in the biodiversity and evolution fields. We are pleased to announce the final two winners: “Managing regime shifts and fisheries collapse on the Great Barrier Reef – the role of ancient DNA” from Professor John Pandolfi and Dr. Cynthia Riginos of the University of Queensland; and “Depth adaptation and scope for vertical connectivity in scleractinian corals” from Dr. Greg Torda of James Cook University.
Developed by global genomics company BGI, the BGISEQ-500 genome sequencer (Zebra) will operate from the company’s new Australian headquarters at the QIMR Berghofer Medical Research Institute since May 2017. It is the only genomics sequencer of its kind in the Southern Hemisphere. A ceremony was held today to mark the official launch of BGI’s new Southern Hemisphere genomics laboratory and the unveiling of the sequencer. Keep reading
Queensland's innovation agenda has received a boost with one of the world's largest gene sequencing institutes choosing to map out its Asian-Pacific expansion from Brisbane. BGI officially opened its new Australian and Asia Pacific headquarters at the QIMR Berghofer Medical Research Institute in Brisbane. BGI President and co-found Professor Jian Wang says the strength of Queensland’s existing life science institutions, industries and social network made it an obvious choice for BGI’s R&D and commercialisation centre for Asia Pacific. Keep reading
QIMR Berghofer Medical Research Institute and the Chinese genomics organisation BGI have entered into an agreement that will promote collaboration on a genomics-based research and education program. The Memorandum of Understanding was signed at a meeting between the two world-leading research bodies in October 2016 in Shenzhen. Keep reading
MGI, the manufacturing subsidiary under BGI Corporation, has received China Food and Drug Administration (CFDA) certification for its latest two models of Next Generation genetic sequencers. MGISEQ-2000 and MGISEQ-200 sequencers have been granted the Medical Device Registration Certificate by CFDA on 25th June 2018, which makes BGI the first organisation in China to receive CFDA certification for Next Generation sequencing diagnostic products and medical devices. These sequencers will not just play an important role in scientific research, but also contribute to a wide range of applications in clinical medicine. Read the full media release here.
MGI Tech Co., Ltd. (MGI), a subsidiary of BGI Group, is committed to enabling effective and affordable healthcare solutions for all. Based on its proprietary technology, MGI produces sequencing devices, equipment, consumables and reagents to support life science research, medicine and healthcare.